公开(公告)号：US20230248667A1

公开(公告)日：2023-08-10

申请号：US18105795

申请日：2023-02-03

申请人： Aurobindo Pharma Ltd

发明人： Soumyajit Behera ,  Satheesh Kumar Gajjala ,  Nilesh Bhandari ,  Nagaprasad Vishnubhotla ,  Sivakumaran Meenakshisunderam

IPC分类号： A61K31/137 ,  A61K31/495 ,  A61K9/28

CPC分类号： A61K31/137 ,  A61K31/495 ,  A61K9/2893 ,  A61K9/2866 ,  A61K9/282

摘要： This invention relates to dosage forms comprising pseudoephedrine or a salt thereof, for extended-release up to 24 hours, and process of making such dosage forms. This invention provides a non-osmotic extended-release dosage form comprising pseudoephedrine hydrochloride which can be administered to patients who need and/or desire a decongestant medication up to 24 hours. This invention also relates to dosage forms comprising pseudoephedrine or a salt thereof and cetirizine or levocetirizine or its salts thereof for extended-release up to 24 hours, and process of making such dosage forms.

公开(公告)号：US20210177822A1

公开(公告)日：2021-06-17

申请号：US17119250

申请日：2020-12-11

申请人： Aurobindo Pharma Ltd.

发明人： Saravanan Kannusamy ,  Prabhakaran Chakkirala ,  Rakesh Sarkar ,  Sivakumaran Meenakshisunderam

IPC分类号： A61K31/4468 ,  A61K9/48 ,  A61K9/00

摘要： The present invention relates to prepare pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof, processes for manufacturing said pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof. Also pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

公开(公告)号：US10759772B2

公开(公告)日：2020-09-01

申请号：US16097777

申请日：2017-04-28

申请人： AUROBINDO PHARMA LIMITED ,  Senthilkumar Natrajan ,  Kishore Karumanchi ,  Vittal Tangirala ,  Sivakumaran Meenakshisunderam

发明人： Senthilkumar Natrajan ,  Kishore Karumanchi ,  Vittal Tangirala ,  Sivakumaran Meenakshisunderam

IPC分类号： C07D309/10 ,  C07D207/12 ,  C07C31/10 ,  C07D207/16 ,  C07C31/20

摘要： The present invention relates to a process For the preparation of Dapagliflozin DL-Proline co-crystal and its use in the preparation/purification of Dapagliflozin. The invention also provides a process for the preparation of Dapagliflozin (R,S)-1.2-propanediol monohydrate.

公开(公告)号：US20180008547A1

公开(公告)日：2018-01-11

申请号：US15548063

申请日：2016-02-01

申请人： Shridhar INAGANTI ,  Venugopala CHOKKASANDRA JAYARAMA REDDY ,  Jayant KARAJGI ,  Sivakumaran MEENAKSHISUNDERAM ,  AUROBINDO PHARMA LTD

发明人： Shridhar Inaganti ,  Venugopala Chokkasandra Jayarama Reddy ,  Jayant Karajgi ,  Sivakumaran Meenakshisunderam

IPC分类号： A61K9/48 ,  A61K38/10

CPC分类号： A61K9/4808 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K38/10

摘要： The present invention relates to stable oral composition comprising linaclotide or its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates, process of preparation thereof and methods of using the same.

公开(公告)号：US08772491B2

公开(公告)日：2014-07-08

申请号：US13261551

申请日：2011-06-20

申请人： Anand Gopalkrishna Kamat ,  Joseph Prabahar Koilpillai ,  Naga Trinadhachari Ganala ,  Venkata Lakshmi Upputuri ,  Venkata Balalji Boddu ,  Sivakumaran Meenakshisunderam

发明人： Anand Gopalkrishna Kamat ,  Joseph Prabahar Koilpillai ,  Naga Trinadhachari Ganala ,  Venkata Lakshmi Upputuri ,  Venkata Balalji Boddu ,  Sivakumaran Meenakshisunderam

IPC分类号： C07D453/02

CPC分类号： C07D453/02

摘要： The present invention relates to a process for the preparation of Solifenacin succinate by condensing a compound of formula (IVb) with (RS)-3-quinuclidinol, wherein, R represents methyl, ethyl, isopropyl; to produce a diastereomeric mixture of (1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic acid (3RS)-1-azabicyclo[2.2.2]oct-3-yl ester, which is treated with succinic acid in a solvent or mixture of solvents to produce optically pure Solifenacin succinate, Formula (X).

摘要翻译： 本发明涉及通过将式（IVb）化合物与（RS）-3-奎宁环醇缩合制备琥珀酸索非那新的方法，其中R代表甲基，乙基，异丙基; （1S）-3,4-二氢-1-苯基-2（1H） - 异喹啉羧酸（3RS）-1-氮杂双环[2.2.2]辛-3-基酯的非对映体混合物，其用 琥珀酸在溶剂或溶剂混合物中以产生光学上纯的索利福宁琥珀酸盐，式（X）。

公开(公告)号：US08563728B2

公开(公告)日：2013-10-22

申请号：US13261135

申请日：2010-07-07

申请人： Sambhu Prasad Sarma Mallela ,  Sukumar Nandi ,  Balanarasimha Reddy Gona ,  Naresh Akkina ,  Rani Ananta ,  Islam Aminul ,  Sivakumaran Meenakshisunderam

发明人： Sambhu Prasad Sarma Mallela ,  Sukumar Nandi ,  Balanarasimha Reddy Gona ,  Naresh Akkina ,  Rani Ananta ,  Islam Aminul ,  Sivakumaran Meenakshisunderam

IPC分类号： C07D221/18

CPC分类号： C07J73/005

摘要： The present invention provides an improved process for the preparation of Dutasteride (I) which comprises: (i) reacting 4-aza-5α-androst-1-en-3-one-17β-carboxylic acid (VII), Formula VII with sulfonic acid anhydride (RSO2)2O in presence of base to produce an intermediate compound of Formula (XIII), wherein R represents C1-6 alkyl, C1-6 halo alkyl, C6-10 aryl, halo aryl; (ii) condensing compound of Formula (XIII) with 2,5-bis(trifluoromethyl)aniline (III), Formula (III) in the presence or absence of a base to produce Dutasteride (I).

摘要翻译： 本发明提供了一种改善的度他雄胺（I）的制备方法，其包括：（i）使4-氮杂-5α-雄甾-1-烯-3-酮-17β-羧酸（VII）与式 （XIII）的中间体化合物，其中R表示C 1-6烷基，C 1-6卤代烷基，C 6-10芳基，卤代芳基; （ii）在存在或不存在碱的情况下将式（XIII）化合物与2,5-双（三氟甲基）苯胺（III），式（III）缩合得到度他雄胺（I）。

公开(公告)号：US08236991B2

公开(公告)日：2012-08-07

申请号：US12451872

申请日：2008-06-05

申请人： V Raghava Reddy Ambati ,  Srinivas Garaga ,  Ramesh Dandala ,  Sivakumaran Meenakshisunderam

发明人： V Raghava Reddy Ambati ,  Srinivas Garaga ,  Ramesh Dandala ,  Sivakumaran Meenakshisunderam

IPC分类号： C07C21/00 ,  C07D277/22 ,  C07D277/28

CPC分类号： C07C213/10 ,  C07C215/28

摘要： The present invention relates to the purification of (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-1,6-diphenylhexane (III) by making its crystalline acid addition salt, which can be used as such to produce Lopinavir/Ritonavir with high purity and yield. Formula III

摘要翻译： 本发明涉及通过制备其结晶酸加成盐来纯化（2S，3S，5S）-5-氨基-2-N，N-二苄基氨基-3-羟基-1,6-二苯基己烷（III），其可以 用于生产具有高纯度和产率的洛匹那韦/利托那韦。 公式三

公开(公告)号：US07164022B2

公开(公告)日：2007-01-16

申请号：US11252860

申请日：2005-10-18

申请人： Ramesh Dandala ,  Divvela Venkata Naga Srinvasa Rao ,  Koilpillai Joseph Prabahar ,  Gollapalli Venkateswara Rao ,  Meenakshisunderam Sivakumaran

发明人： Ramesh Dandala ,  Divvela Venkata Naga Srinvasa Rao ,  Koilpillai Joseph Prabahar ,  Gollapalli Venkateswara Rao ,  Meenakshisunderam Sivakumaran

IPC分类号： C07D221/18 ,  C07D221/04

CPC分类号： C07D221/18

摘要： The present invention relates to an improved process for the preparation of pure Finasteride of Formula I, which comprises converting dihydrofinasteride to finasteride through novel protected dihydrofinasteride and protected finasteride intermediates.

摘要翻译： 本发明涉及一种制备式I的纯非那雄胺的改进方法，其包括通过新型受保护的二氢芬西酰头孢甾酮和受保护的非那雄胺中间体将二氢芬太昔妥转化为非那雄胺。

公开(公告)号：US11969413B2

公开(公告)日：2024-04-30

申请号：US17510797

申请日：2021-10-26

申请人： Aurobindo Pharma Ltd

发明人： Saravanan Kannusamy ,  Prabhakaran Chakkirala ,  Nagaprasad Vishnubhotla ,  Sivakumaran Meenakshisunderam

IPC分类号： A61K9/20 ,  A61K31/4375

CPC分类号： A61K31/4375 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2077

摘要： This present invention relates to pharmaceutical composition comprising Deutetrabenazine. The invention also relates to the methods of preparation of the composition having improved stability and dissolution profile and used for the treatment of chorea associated with Huntington disease and tardive dyskinesia.

公开(公告)号：US20230390254A1

公开(公告)日：2023-12-07

申请号：US18204237

申请日：2023-05-31

申请人： Aurobindo Pharma Ltd

发明人： Saravanan KANNUSAMY ,  Koteswararao GUDE ,  Nagaprasad VISHNUBHOTLA ,  Sivakumaran MEENAKSHISUNDERAM

IPC分类号： A61K31/437 ,  A61K9/20

CPC分类号： A61K31/437 ,  A61K9/2027 ,  A61K9/2013 ,  A61K9/2009 ,  A61K9/2054 ,  A61K9/2018 ,  A61K9/2031

摘要： The present invention relates to a stable immediate release tablet compositions of Ubrogepant and one or more pharmaceutically acceptable excipients and a process for preparation thereof.